



an Open Access Journal by MDPI

## The Role of Real World Evidence in Oncology: Opportunities, Results and Limitations

Guest Editor:

**Soo Jin Seung**

Sunnybrook Health Sciences  
Centre, Toronto, ON, Canada

Deadline for manuscript  
submissions:

**closed (31 October 2022)**

### Message from the Guest Editor

Real-world evidence has been a popular phrase for the last 10 years, but could be considered the re-branding of clinical data that does not meet the typical randomized phase III study criteria often included in HTA submissions. Variations in patient populations in oncology are another reason why RWE is gaining prominence with its ability to address uncertainty and data gaps and is being accepted by decision-makers. Access and the use of cancer registries and linkages to administrative databases is flourishing, resulting in the demand for more clinical, quality of life and utility data outside the confines of a clinical trial and more representative healthcare practices. However, there are still challenges faced, from privacy and legal restrictions to lack of consensus by regulatory bodies in terms of establishing RWE guidelines. The goals are to publish research in any oncology indication that uses real-world data to determine outcomes, promote young investigators, and to highlight similarities and difference between regions and countries.



[mdpi.com/si/133710](https://mdpi.com/si/133710)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

## Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase,** and **other databases.**

**Journal Rank:** JCR - Q2 (*Oncology*)

## Contact Us

---

Current Oncology Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/currnocol](http://mdpi.com/journal/currnocol)  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)  
[X@CurrentOncology](https://twitter.com/CurrentOncology)